Search Results
Your search for ,aLl matches 18304 pages
Showing 15301 - 15350Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Marcia S. Brose, MD, PhD, of Abramson Cancer Center of the University of Pennsylvania, and colleagues ...
Conquer Cancer Foundation Past Grant Recipients Present Research Advances in Melanoma and Ovarian Cancer at 2014 ASCO Annual Meeting
The Conquer Cancer Foundation has an excellent track record of finding and funding the most promising young investigators. Past recipients Joyce F. Liu, MD, MPH, and Antoni Ribas, MD, PhD, received funding from the Conquer Cancer Foundation early in their career and at the 2014 ASCO Annual Meeting...
Look for Changes to Cancer.Net’s Design and Navigation
Cancer.Net, ASCO’s patient information website, is in the process of updating the design and is now offering an easier way to navigate the site. Based on extensive testing, the site’s new look and feel is designed to improve each user’s experience. The changes will keep Cancer.Net up-to-date with...
ASCO Invites Widespread Use of Federally Funded Research Badge
To raise awareness of the importance of federally funded biomedical research that improves the lives of people worldwide, ASCO has created a badge that organizations and individuals can use to publicize research that has received federal funding. To use the Federally Funded Research badge,...
ASCO’s Cancer Survivorship Compendium Offers Oncologists Help With Survivorship Care
It has been almost 10 years since the Institute of Medicine released its influential report, “From Cancer Patient to Cancer Survivor: Lost in Transition,” in which it stressed that all patients completing cancer treatment should receive a survivorship care plan. Since then, the need to help...
ASCO’s 50th Anniversary: Past Presidents Recall Top Issues During Their Terms
In a series of articles on the American Society of Clinical Oncology’s CancerProgress.Net website, past ASCO presidents are sharing their recollections of the major issues during their terms. Emil J Freireich, MD, FASCO, (1980–1981), remembered that during his presidency, ASCO began the process of...
Illumination to Innovation: Transforming Data Into Learning
“Illumination” is a provocative word, evoking as it does the banishment of the darkness of ignorance by the light of new knowledge. Today, we are benefiting from a steady stream of new knowledge about the molecular basis of cancer and the interaction between host and tumor immunology. The concept...
Expert Point of View: Jean-Yves Douillard, MD, PhD
Commenting on the RECOURSE data,1 ESMO spokesperson Jean-Yves Douillard, MD, PhD, Professor of Medical Oncology, Institut de Cancérologie de l’Ouest (ICO) René Gauducheau, Saint-Herblain, France, said, “The phase III trial of TAS-102 is a global study and confirms the results of the phase II study...
Phase III Trial Shows Improved Survival With TAS‑102 in Metastatic Colorectal Cancer Refractory to Standard Therapies
The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.1 “Around 50% of patients with...
FDA Drug Safety Communication: Docetaxel May Cause Symptoms of Alcohol Intoxication
The U.S. Food and Drug Administration (FDA) has issued a drug safety communication to health-care professionals warning that docetaxel contains ethanol, which may cause patients to experience intoxication during and after treatment. FDA is revising the labels of all docetaxel drug products to warn...
FDA Grants Breakthrough Therapy Designation to Blinatumomab for Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to blinatumomab for adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an investigational bispecific T-cell engager antibody...
ASPHO Abstracts Cover Broad Range of Topics
More than 400 abstracts—a record—were submitted for the 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology in Chicago. Here is a small sampling of those studies, with comments from the abstract authors. Token Economy to Improve Compliance BMT Bucks form the basis of a...
Federally Funded Trials Praised—and Underfunded
All four studies presented at the 2014 ASCO Annual Meeting Plenary Session were at least partially funded by federal dollars, bringing long overdue attention to the value of federally supported cancer research. Perhaps because of this high visibility, ASCO leaders took to the soapbox to sound the...
Investigational Immunotherapy Demonstrates Response in Patients With PD-L1–Positive Metastatic Bladder Cancer
The investigational immunotherapy agent MPDL3280A (also known as anti-PDL1) produced an overall response rate of 43% in a phase I study of patients previously treated for metastatic urothelial bladder cancer whose tumors were characterized as programmed death ligand 1 (PD-L1)-positive. Results of...
FDA Approves Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to belinostat (Beleodaq), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). “This is the...
FDA Grants Breakthrough Therapy Designation to Investigational Chimeric Antigen Receptor Therapy for Relapsed/Refractory ALL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The Breakthrough Therapy filing...
Expert Point of View: Wendy Demark-Wahnefried, PhD, RD
Wendy Demark-Wahnefried, PhD, RD, Professor and Webb Endowed Chair of Nutrition Sciences at the University of Alabama at Birmingham, formal discussant for the SHAPE-2 and LEAN trials at the ASCO Annual Meeting, emphasized the importance of weight loss, but noted that it can be challenging for...
Breast Cancer–Related Benefits of Weight Loss
Obesity and physical inactivity are associated with an increased risk of developing and dying of breast cancer via several proposed mechanisms. Two studies presented at the 2014 ASCO Annual Meeting explored the relationships among exercise, weight loss, and breast cancer risk. One study was...
Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy
The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a study from the Abramson Cancer Center and the Perelman School of Medicine at...
Impressive Delay in Thyroid Cancer Progression Achieved With Lenvatinib
The investigational tyrosine kinase inhibitor lenvatinib reduced disease progression by 79%, as compared to placebo, in patients with metastatic differentiated thyroid cancer that is refractory to radioactive iodine in the phase III SELECT trial. These findings were presented at the 2014 ASCO...
Benefit Confirmed for Adjuvant Oxaliplatin in Rectal Cancer
Patients with curatively resected rectal cancer are more likely to be disease-free at 3 years after treatment with an oxaliplatin-containing regimen than with fluorouracil (5-FU)/leucovorin, Korean investigators of the phase II multicenter ADORE trial reported at the ASCO Annual Meeting.1 Study...
Intralesional Injections Trigger Immune Responses in Melanoma
The emerging approach to treating metastatic melanoma is a full-throttle effort to stimulate an immune response. One of the components of this strategy could be intralesional injections, according to studies presented at the 2014 ASCO Annual Meeting. T-VEC Oncolytic Immunotherapy Talimogene...
Multiple Myeloma Studies Explore Roles of Panobinostat in Relapsed/Refractory Disease and Thalidomide Compared to Lenalidomide as Part of Initial Therapy
At the 2014 ASCO Annual Meeting, one phase III trial confirmed the promise of a novel agent in advanced multiple myeloma, while another cooperative group trial returned some rather surprising results in newly diagnosed myeloma patients. Panobinostat Doubles Response, Prolongs Remission The phase...
Stakeholders Are Uniting Around Value in Cancer Care
Judging from its visibility at the 2014 ASCO Annual Meeting, the concept of “value” in cancer care has reached critical mass. “ASCO is leading this difficult discussion on value in cancer care. This had to happen,” said Clifford A. Hudis, MD, FACP, Immediate Past President of ASCO and Chief of the ...
Take-Home Messages From ASCO's Immediate Past President
The ASCO Post recently spoke with ASCO Immediate Past President Clifford A. Hudis, MD, FACP, about his term as ASCO President. Dr. Hudis discussed his thoughts on ASCO today and shared his perspective on a number of important issues in oncology, including value in cancer care, big data, and more....
Expert Point of View: Howard A. Fine, MD and Martin J. van den Bent, MD
Session moderator Howard A. Fine, MD, the Anne Murnick Cogan and David H. Cogan Professor of Oncology and Director of the Brain Tumor Center at New York University Cancer Institute, shared his enthusiasm over the findings of the RTOG 9802 study. “I don’t know of any other tumor type where the...
Considerable Extension of Survival Achieved With Conventional Treatment in Grade 2 Glioma
Long-term results from the Radiation Therapy Oncology Group (RTOG) 9802 study in high-risk grade 2 gliomas were presented at the 2014 ASCO Annual Meeting. The study’s mature analysis showed a 41% reduction in mortality at 5 years with combination radiation therapy followed by six cycles of PCV...
National Ovarian Cancer Coalition Featured in New York’s Rockefeller Center Window During August
Throughout August, the National Ovarian Cancer Coalition (NOCC) is being featured in the highly coveted 10 Rockefeller Plaza showcase window in New York. The space is being donated by EHE International, a historic preventive health-care company, dedicated to proactive health-care management. The...
What Do Humans and Laboratory Rats Have in Common?
The requirements for sound evidence of a drug’s therapeutic benefit have translated laboratory experience to human testing. In the laboratory, experimental animals give their lives to lethal testing of drugs and scientific analysis. LD50, the terminology denoting an anticipated 50% death rate of...
Everolimus Did Not Improve Survival in Hepatocellular Cancer After Progression on Sorafenib
“Despite the strong scientific rationale and preclinical data, everolimus [Afinitor] plus best supportive care failed to improve survival over placebo plus best supportive care” among patients with advanced hepatocellular cancer that progressed during or after receiving sorafenib (Nexavar), or who...
High False-Positive Rate of Elevated CEA Seen in Patients With Resected Colorectal Cancer
A retrospective study finding a 49% false-positive of carcinoembryonic antigen (CEA) testing among patients with a history of resected colorectal cancer, “suggests that confirmation of an ongoing increase in CEA level should be universal practice before an extensive workup is initiated,” Anya...
Ongoing Clinical Trials Actively Recruiting Patients With Bladder Cancer
The information in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with bladder cancer. The list includes randomized and nonrandomized phase 0 to III studies as well as observational clinical trials evaluating new therapies, surgical techniques, and...
‘Reasonable’ to Advise Men Who Have Had Vasectomies That They Have a Small Increased Risk for Lethal Prostate Cancers
Long-term results from the Health Professionals Follow-up Health Study have shown a 20% increased risk of advanced prostate cancer and a 19% increased risk of lethal prostate cancer among men who had vasectomies.1 According to the study’s lead author, Mohummad Minhaj Siddiqui, MD, it is...
Dignity, Personhood, and the Culture of Medicine
Cancer patients need more than good health care: they need health caring, according to palliative care specialist Harvey M. Chochinov, MD, PhD, Distinguished Professor of Psychiatry at the University of Manitoba and Director of the Manitoba Palliative Care Research Unit, CancerCare Manitoba. Health ...
Mutations in IGF Pathway Genes Associated With Prostate Cancer Mortality
In a study reported in the Journal of the National Cancer Institute, Cao and colleagues identified mutations in insulin-like growth factor (IGF) pathway genes that were significantly associated with mortality in prostate cancer. Analysis of 530 single nucleotide polymorphisms (SNPs) in 26 IGF...
Prolyl Hydroxylase Inhibition Protects Against Gastrointestinal Radiation Toxicity
In a study reported in Science Translational Medicine, Taniguchi and colleagues found that inhibition of prolyl hydroxylase by genetic knockout or inhibition of all prolyl hydroxylase domain isoforms by the small-molecule dimethyloxallyl glycine (DMOG) resulted in promotion of protection against...
Spleen Tyrosine Kinase Inhibition Has Promise in High-Risk Precursor B-Cell ALL
In a study reported in Science Translational Medicine, Perova and colleagues found that pre–B-cell receptor–independent spleen tyrosine kinase signaling was necessary for leukemic B-cell survival and proliferation in a mouse model. Investigation of samples from pediatric and adult B-cell acute...
FDA Commissioner Margaret A. Hamburg’s Statement on the Surgeon General’s Call to Action to Prevent Skin Cancer
Each year, thousands of Americans are diagnosed with some form of skin cancer. The Surgeon General’s Call to Action to prevent skin cancer is important especially during these hot summer months when many of us spend extra time in the sun. Over the last few years, the FDA has taken a number of...
Surgeon General Call to Action to Prevent Skin Cancer
On July 29, 2014, the Surgeon General issued a Call to Action urging immediate action steps to prevent skin cancer. The report encourages increased awareness of the disease and calls for immediate and collaborative actions to reduce its risk. Nearly 5 million people are treated for skin cancer in...
Cancer Survivor and Patient Advocate Michael S. Katz, MBA, Has Helped Alter the Standard of Care for Myeloma Survivors
Michael S. Katz, MBA, has lived longer than any of his doctors thought he would. A two-time cancer survivor, Mr. Katz was diagnosed, first with multiple myeloma in 1990 and then with colorectal cancer in 2008, and has spent the past 2 decades tirelessly advocating for patients with cancer. The...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Taking Charge of Your Care
The first sign I had that something might be wrong was an uncontrollable itch all over my body. Although I had never had anything like that before, the problem was easy to initially dismiss. I’m a respiratory therapist and visit patients in their homes daily, so I chalked up the itchiness to an...
Don Shula Foundation Donates $1.5 Million to Moffitt Cancer Center
The Don Shula Foundation is donating $1.5 million to Moffitt Cancer Center to establish The Don Shula Breast Cancer Research Fund (The Shula Fund). Scientists at Moffitt will use The Shula Fund to support cutting-edge research projects that will generate new treatment and prevention strategies for...
Focus on the Florida Society of Clinical Oncology
The Florida Society of Clinical Oncology (FLASCO) was founded in 1977, just 13 years after the founding of ASCO. Today, the Society has had such an impact on the practices of medical, radiation, surgical, gynecologic, and pediatric oncologists throughout the state, membership has risen to over...
Michael Douglas Shares His Experience With Stage IV Oropharyngeal Cancer
Academy Award winning actor and producer Michael Douglas was the guest of honor at the opening day of the International Federation of Head and Neck Oncologic Societies (IFHNOS) 5th World Congress on July 27 in New York (see page 22 for more on the World Congress). He came not to plug the release of ...
FDA Takes Steps to Help Ensure the Reliability of Certain Diagnostic Tests
The U.S. Food and Drug Administration (FDA) recently took important steps to ensure that certain tests used by health-care professionals to help diagnose and treat patients provide accurate, consistent, and reliable results. First, the FDA is issuing a final guidance on the development, review, and ...
Book Excerpt: Family
I've witnessed incredible courage and zest for life among so many patients from so many walks of life—individuals committed to helping others in spite of their own adversity. Forty years ago, when survival for patients with multiple myeloma was a matter of months, I knew that every person I sat...
Oncologists Tell Inspiring Stories of What It’s Like to Treat Cancer in The Big Casino
Title: The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful StoriesEditors: Stan Winokur, MD, and Vincent CoppolaPublishing Platform: CreateSpacePublication date: May 2014Price: $9.99; Paperback, 160 pages In May, Stan Winokur, MD, and co-editor Vincent Coppola, published The...
Lung Cancer Alliance Commends National Cancer Institute for Its New Scientific Framework for Small Cell Lung Cancer
The National Cancer Institute (NCI) recently presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer. The report, entitled “Scientific Framework for Small Cell Lung Cancer (SCLC)” was mandated by the Recalcitrant Cancer Research...
Facing Cancer Together
David sits at his desk, tapping angrily. He’s tired of his abusive, ignorant boss, the VP for regional sales. The man’s sales targets are absurdly high, he’s impossible to reach on the phone, his “motivational” speeches evoke the stress of Glengarry Glen Ross, and even his fake all-light-brown hair ...
